Kovaksin sahifasining manbasini koʻrish

'''BBV152''' (savdo nomi: ''Covaxin'', '''Kovaksin''') – Bharat Biotech kompaniyasi tomonidan [[Hindiston]] Tibbiy Tadqiqotlar Kengashi bilan hamkorlikda ishlab chiqilgan [[COVID-19 koronavirus infeksiyasi|COVID-19]] ga qarshi inaktivatsiyalangan [[Viruslar|virus]] vaksinasi.

== 3-bosqich klinik sinovlari ==
2020-yil noyabr oyida Kovaksin III bosqich sinovlarini oʻtkazishga ruxsat oldi. Sinov 18 yosh va undan katta yoshdagi koʻngillilar orasidagi randomizatsiyalangan qoʻshaloq koʻr platsebo-nazorat ostidagi sinovni oʻz ichiga oladi<ref>{{veb manbasi|lang=en|url=https://clinicaltrials.gov/ct2/show/NCT04641481|title=An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers — Full Text View — ClinicalTrials.gov|website=clinicaltrials.gov|accessdate=2020-12-21|archive-date=2020-11-26|archive-url=https://web.archive.org/web/20201126061700/https://clinicaltrials.gov/ct2/show/NCT04641481|deadlink=no}}</ref>. III bosqich sinovlarida butun Hindistondan jami 26 000 ga yaqin koʻngillilar ishtirok etadi<ref>{{yangiliklar manbasi|accessdate=2020-12-21|coauthors=Special Correspondent|date=2020-10-23|id=0971-751X|location=Hyderabad|website=The Hindu|title=Coronavirus {{!}} Covaxin Phase III trial from November|url=https://www.thehindu.com/business/Industry/covaxin-phase-iii-trial-from-november/article32928549.ece|archivedate=2020-11-29|archiveurl=https://web.archive.org/web/20201129154609/https://www.thehindu.com/business/Industry/covaxin-phase-iii-trial-from-november/article32928549.ece}}</ref><ref>{{Статья|ссылка=https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2|автор=Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Dharam, Narasimha Reddy Molugu, Sai D. Prasad|заглавие=Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine — BBV152|год=2020-09-12|язык=en|издание=bioRxiv|страницы=2020.09.09.285445|doi=10.1101/2020.09.09.285445|archivedate=2020-12-11|archiveurl=https://web.archive.org/web/20201211233853/https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2}}</ref>. III bosqich sinovlari mamlakatning bir nechta shtatlaridan, jumladan, Dehli, [[Karnataka]] va Gʻarbiy Bengaldan tashkil topgan jami 22 ta markazlarni qamrab oladi, yaqin orada ularga yana koʻplab boshqa shtatlar qoʻshilishi kutilmoqda<ref>{{veb manbasi|lang=en|url=https://indianexpress.com/article/india/bharat-biotech-begins-covaxin-phase-iii-trials-7055237/|title=Bharat Biotech begins Covaxin Phase III trials|website=The Indian Express|date=2020-11-18|accessdate=2020-12-21|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122061216/https://indianexpress.com/article/india/bharat-biotech-begins-covaxin-phase-iii-trials-7055237/|deadlink=no}}</ref><ref>{{veb manbasi|lang=en|url=https://www.livemint.com/news/india/coronavirus-vaccine-in-india-these-states-have-started-phase-3-trials-of-bharat-biotech-covaxin-11606908773897.html|title=List of states that have started phase 3 trials of India's first Covid vaccine|website=mint|date=2020-12-02|accessdate=2020-12-21|archive-date=2021-02-13|archive-url=https://web.archive.org/web/20210213035514/https://www.livemint.com/news/india/coronavirus-vaccine-in-india-these-states-have-started-phase-3-trials-of-bharat-biotech-covaxin-11606908773897.html|deadlink=no}}</ref>.

== Favqulodda foydalanishni tasdiqlash ==
Bharat Biotech kompaniyasi vaksinadan favqulodda holatlarda (EUA) foydalanishga ruxsat olish uchun iltimos bilan Hindiston Hukumatining Hindiston bosh dori vositalari nazoratchisiga (DCGI) murojaat qildi<ref>{{veb manbasi|lang=en|url=https://www.hindustantimes.com/india-news/bharat-biotech-seeks-emergency-use-authorization-for-covid-19-vaccine-govt-source/story-HmmD0JnniJeigdF6xmjxBO.html|title=Bharat Biotech seeks emergency use authorization for Covid-19 vaccine|website=Hindustan Times|date=2020-12-07|accessdate=2020-12-21|archive-date=2020-12-24|archive-url=https://web.archive.org/web/20201224121817/https://www.hindustantimes.com/india-news/bharat-biotech-seeks-emergency-use-authorization-for-covid-19-vaccine-govt-source/story-HmmD0JnniJeigdF6xmjxBO.html|deadlink=no}}</ref>. Bu Serum Institute of India va Pfizerdan keyingi vaksinani favqulodda holatlarda qoʻllashga ruxsat olish uchun ariza bergan uchinchi firma edi<ref>{{yangiliklar manbasi|accessdate=2020-12-21|coauthors=Special Correspondent|date=2020-12-07|id=0971-751X|location=New Delhi|website=The Hindu|title=Coronavirus {{!}} After SII, Bharat Biotech seeks DCGI approval for Covaxin|url=https://www.thehindu.com/sci-tech/health/coronavirus-serum-institute-seeks-emergency-use-approval-for-covishield-in-india/article33265921.ece|archivedate=2020-12-24|archiveurl=https://web.archive.org/web/20201224142443/https://www.thehindu.com/sci-tech/health/coronavirus-serum-institute-seeks-emergency-use-approval-for-covishield-in-india/article33265921.ece}}</ref>.

2021-yil 3-yanvarda vaksina Hindistonda favqulodda foydalanish uchun tasdiqlangan<ref>{{yangiliklar manbasi|accessdate=2021-01-03|website=BBC News Русская служба|title=Коронавирус в мире: карантин в Англии и Германии, новая вакцина в Индии, Венгрия прощается со "Спутником V"|url=https://www.bbc.com/russian/news-55444084|archivedate=2021-01-03|archiveurl=https://web.archive.org/web/20210103155131/https://www.bbc.com/russian/news-55444084}}</ref>.

== Manbalar ==
{{manbalar}}
<references responsive="1"></references>

[[Turkum:Hind KOVID vaksinalari-19]]
[[Turkum:Tasdiqlanmagan samarali dorilar]]